Anifrolumab
Monoclonal antibody
Evidence outlook
Approved: Systemic Lupus Erythematosus
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Idiopathic Inflammatory Myopathies · Phase 3 · investigational in the USSystemic Sclerosis · Phase 3 · investigational in the US
Also approved (2)
- Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
- Saphnelo: adult patients with systemic lupus erythematosus
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02446912 NCT02446912 · Active Systemic Lupus Erythematosus The study was randomized, double-blind, placebo-controlled, and enrolled 457 participants, with a hard clinical disease-activity endpoint. However, the primary Week 52 SRI(4) comparison for anifrolumab 300 mg was not statistically significant versus placebo (p=0.412), so the trial provides well-designed but inconclusive evidence of benefit. Registry: NCT02446912 | 3 | Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules) 2018-07-17 | Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules) (Week 52): Anifrolumab 150 mg 35/93 (37.6%) | Anifrolumab 300 mg 65/180 (36.1%) vs Placebo 74/184 (40.2%) | Partial signal | link ↗ |
View 4 more trials
NCT02446899 NCT02446899 · Active Systemic Lupus Erythematosus This was a randomized, double-blind, placebo-controlled trial with 373 participants enrolled and 362 participants included in the primary analysis. The primary clinical endpoint, BICLA response at week 52, was met, with 86 of 180 participants receiving anifrolumab versus 57 of 182 receiving placebo responding (p=0.0013). Registry: NCT02446899 | 3 | Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 (Baseline; Week 52) 2018-09-27 | Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 (Baseline; Week 52): Anifrolumab 300 mg 86/180 (47.8%) vs Placebo 57/182 (31.3%) | Reliable signal | link ↗ |
NCT04931563 NCT04931563 · Active Systemic Lupus Erythematosus This was a randomized, quadruple-blind, placebo-controlled trial with 277 participants. Its primary clinical endpoint, BICLA response at Week 52, was met in favor of anifrolumab, with 84 of 138 participants responding compared with 46 of 138 receiving placebo; the reported treatment difference was 28.4 percentage points with a 95% credible interval of 16.3% to 38.0%. Registry: NCT04931563 | 3 | Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo (Week 52) 2025-04-07 | Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo (Week 52): Anifrolumab 300mg 84/138 vs Placebo 46/138 | Reliable signal | link ↗ |
NCT01438489 NCT01438489 · Systemic Lupus Erythematosus Registry: NCT01438489 | 2 | Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169; Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169 2015-04 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
Tulip SC NCT04877691 · Systemic Lupus Erythematosus Registry: NCT04877691 | 3 | British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response (At week 52) 2025-08-22 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Idiopathic Inflammatory Myopathies: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Anifrolumab: this drug | Phase 3 | Monoclonal antibody | Type I interferon receptor subunit 1 (IFNAR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb657 | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Anifrolumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (5)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
August 2027 (2)
September 2027 (1)
What to watch
2028 (4)
January 2028 (1)
What to watch
June 2028 (1)
What to watch
August 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (3)
January 2029 (1)
What to watch
March 2029 (1)
What to watch
April 2029 (1)
What to watch
2030 (1)
September 2030 (1)
What to watch
2032 (1)
December 2032 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent